Bexion Pharmaceuticals

Bexion Pharmaceuticals, Inc. Announces Poster Presentation at ASCO GI 2025 ? COVINGTON, Ky. — Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel, first-in-class biologic therapy to treat solid tumors and chemotherapy-induced peripheral neuropathy (CIPN), today announced a poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 23-25, 2025, in San Francisco, CA. Poster details are included below. ? Poster Details: Session Title: Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus Session Date: January 25, 2025 Abstract Number: TPS320 Abstract Title: “BXQ-350, a novel sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal cancer (mCRC) patients: A phase 1b/2 study.” More details on the conference can be found at the ASCO GI website at https://lnkd.in/gwCs3nqb.

We are thrilled to share that our Chairman, Chuck Scheper, has been named one of the 2025 Great Living Cincinnatians by the Cincinnati USA Regional Chamber. This prestigious recognition highlights not only Chuck’s extraordinary contributions to the communities of Covington and Greater Cincinnati but also his unwavering dedication to making a difference through his compassionate leadership. Chuck has been instrumental in Bexion’s success, serving as investor, ambassador, and Chairman. His leadership, vision, and steadfast support have been pivotal in shaping our journey. Beyond Bexion, Chuck’s impact on our community is considerable—he has donated his time and resources to a variety of causes and led by example with his generosity and commitment to service. We invite you to learn more about Chuck’s incredible story by reading his feature article here - https://lnkd.in/g2t962EN You can also explore the inspiring accomplishments of this year’s other honorees here - https://lnkd.in/giyZ4Fhj On behalf of the entire Bexion team, we extend our heartfelt thanks to Chuck for his guidance, dedication, support, and friendship. Congratulations, Chuck, on this well-deserved honor.

Bexion Pharmaceuticals, Inc. Awarded Grant from The Michael J. Fox Foundation to Advance BXQ-350 ? COVINGTON, Ky. — Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded a grant to Bexion that will fund the preclinical development of BXQ-350 for the treatment of Parkinson’s disease (PD). ? “We are grateful and honored to receive this generous grant from The Michael J. Fox Foundation as we explore the potential of BXQ-350 in neurogenerative diseases including Parkinson’s disease,” said Jim Beach, Chief Executive Officer of Bexion. “We are excited to accelerate our research, which will help address the pressing needs of patients currently lacking effective treatment options.” ? Preclinical and clinical data demonstrate that BXQ-350 is a potent allosteric activator of wild type and mutated glucocerebrosidase (GCase). A key mutation in the GBA gene, which encodes GCase, appears in 5 to 15% of PD patients and is the largest genetic risk for developing the disease. ? “At MJFF, we are constantly seeking and funding innovative research that holds the potential to transform Parkinson’s treatment and bring us closer to a cure,” said Jessica Tome Garcia, PhD, senior scientific portfolio manager at MJFF. “We greatly value the ongoing efforts to test novel therapeutic approaches to advanced targets in PD like GCase.” About BXQ-350 Bexion’s lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional sphingolipid activator protein, Saposin C, and a phospholipid. Multiple Phase 1 clinical trials in adult and pediatric patients have demonstrated a robust safety profile for BXQ-350 with evidence of single agent activity across multiple solid tumor types. Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in chemotherapy-induced peripheral neuropathy, an area of high unmet medical need in patients treated with oxaliplatin and other chemotoxic agents.?

Bexion to Participate in the Jefferies London Healthcare Conference - Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced that the Company will participate in the Jefferies London Healthcare Conference. The conference will be held in?London, UK, from?November 19-21, 2024. To access the full press release- https://lnkd.in/gcabZN2m

https://lnkd.in/eqWU-Yba

Charles R. Scheper, Chairman of the Board of Bexion Pharmaceuticals, Inc. was just recognized by the Cancer Support Community (CSC) for his 25 years of service as a CSC Board?member.?

Please see the Press Release announcing our latest BXQ-350 poster presentation during the American Association for Cancer Research (AACR) Meeting: https://lnkd.in/eBmYqyM8

Congratulations to the City of Covington for just receiving a budget grant from the state of Kentucky for $150M to to establish the “Commonwealth Center for Biomedical Excellence,” an innovation, entrepreneurship, and life sciences campus in Covington, KY. Bexion is incredibly proud to be an important part of the emerging cluster of Life Science Companies along with CTI and Gravity Diagnostics in Covington. Very exciting! Scott Shively - CEO, Bexion Pharmaceuticals Your document has finished loading